Background The RAS/MAPK pathway has emerged as a critical for therapeutic targeting in spectrum of solid tumor and hematological malignances. Inhibitors MAPK targets, such RAS, BRAF, or MEK have been approved the treatment cancer either monotherapy combination. However, there no drug ERK1/2, terminal kinases Ras-Raf-MEK-ERK signal transduction cascade. combination ERK1/2 inhibitor checkpoint in...

A Correction to this paper has been published: 10.1007/s00222-017-0749-x

An error occurred during the publication of a number of articles in BMC Palliative Care. These articles were erroneously published in volume number 17, which is listed with a publication date of 2018. However, these articles were published in final form in the year 2017. Provided below are the actual publication dates and the correct citation for each affected article. Please note that the cita...

a Departamento de Engenharia de Engenharia Civil, Arquitectura e Georrecursos, Centro de Recursos Naturais e Ambiente, Instituto Superior Técnico, Technical University of Lisbon (TULisbon), Av. Rovisco Pais, 1049-001 Lisboa, Portugal b Universidade Técnica de Lisboa, Instituto Superior de Agronomia, Unidade de Investigação de Química Ambiental, Tapada da Ajuda, 1349-017 Lisboa, Portugal c Labor...